Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24.

<p>Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24.</p>

Saved in:

Bibliographic Details
Main Author:	Tosi M. Mwakyandile (16408705) (author)
Other Authors:	Grace A. Shayo (15198131) (author), Philip G. Sasi (16408708) (author), Peter P. Kunambi (12878497) (author), Ferdinand M. Mugusi (7372538) (author), Godfrey Barabona (11339337) (author), Takamasa Ueno (240575) (author), Eligius F. Lyamuya (8772767) (author)
Published:	2025
Subjects:	Medicine Cell Biology Pharmacology Biotechnology Immunology Developmental Biology Cancer Infectious Diseases Virology sup >+</ sup na &# 239 competing risk analyses 50 rna copies 42 (− 2 63 versus 3 5 %), mortality 430 recruited participants 131 participants completing 06 (− 1 xlink "> pactr202003522049711 secondary outcomes assessed plhiv initiating art based antiretroviral therapy aspirin promisingly appears treatment arm comparisons versus − 0 xlink "> low 1 expression ). xlink "> secondary outcomes antiretroviral therapy versus 98 versus 34 cause mortality adjunct treatment placebo arm aspirin arm 53 ). 04 ). treat strategy soluble cd14 remains high randomly assigned primary outcome placebo daily placebo arms people living monocyte activation mg aspirin median change larger decrease immunologic benefits group placebo dr co dose aspirin cell exhaustion cell activation cd4 count aids complications
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items